8-K - Allarity Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Matters. On February 3, 2026, Allarity Therapeutics, Inc. (the “Company”) announced that enrollment has opened for its new Phase 2 clinical trial evaluati

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated February 3, 2026. 104 Cover Page Interactive Data File (em

Exhibits Only

Source Document

Exhibits (2)

8-K

CURRENT REPORT

99.1

PRESS RELEASE, DATED FEBRUARY 3, 2026